» Articles » PMID: 39677660

Intracellular Pocket Conformations Determine Signaling Efficacy Through the Opioid Receptor

Overview
Journal bioRxiv
Date 2024 Dec 16
PMID 39677660
Authors
Affiliations
Soon will be listed here.
Abstract

It has been challenging to determine how a ligand that binds to a receptor activates downstream signaling pathways and to predict the strength of signaling. The challenge is compounded by functional selectivity, in which a single ligand binding to a single receptor can activate multiple signaling pathways at different levels. Spectroscopic studies show that in the largest class of cell surface receptors, 7 transmembrane receptors (7TMRs), activation is associated with ligand-induced shifts in the equilibria of intracellular pocket conformations in the absence of transducer proteins. We hypothesized that signaling through the opioid receptor, a prototypical 7TMR, is linearly proportional to the equilibrium probability of observing intracellular pocket conformations in the receptor-ligand complex. Here we show that a machine learning model based on this hypothesis accurately calculates the efficacy of both G protein and -arrestin-2 signaling. Structural features that the model associates with activation are intracellular pocket expansion, toggle switch rotation, and sodium binding pocket collapse. Distinct pathways are activated by different arrangements of the ligand and sodium binding pockets and the intracellular pocket. While recent work has categorized ligands as active or inactive (or partially active) based on binding affinities to two conformations, our approach accurately computes signaling efficacy along multiple pathways.

References
1.
Lomize A, Pogozheva I, Mosberg H . Anisotropic solvent model of the lipid bilayer. 2. Energetics of insertion of small molecules, peptides, and proteins in membranes. J Chem Inf Model. 2011; 51(4):930-46. PMC: 3091260. DOI: 10.1021/ci200020k. View

2.
Ravindranathan A, Joslyn G, Robertson M, Schuckit M, Whistler J, White R . Functional characterization of human variants of the mu-opioid receptor gene. Proc Natl Acad Sci U S A. 2009; 106(26):10811-6. PMC: 2705556. DOI: 10.1073/pnas.0904509106. View

3.
Leysen J, Gommeren W, NIEMEGEERS C . [3H]Sufentanil, a superior ligand for mu-opiate receptors: binding properties and regional distribution in rat brain and spinal cord. Eur J Pharmacol. 1983; 87(2-3):209-25. DOI: 10.1016/0014-2999(83)90331-x. View

4.
Wingler L, Elgeti M, Hilger D, Latorraca N, Lerch M, Staus D . Angiotensin Analogs with Divergent Bias Stabilize Distinct Receptor Conformations. Cell. 2019; 176(3):468-478.e11. PMC: 6475118. DOI: 10.1016/j.cell.2018.12.005. View

5.
Piekielna-Ciesielska J, Artali R, Azzam A, Lambert D, Kluczyk A, Gentilucci L . Pharmacological Characterization of µ-Opioid Receptor Agonists with Biased G Protein or β-Arrestin Signaling, and Computational Study of Conformational Changes during Receptor Activation. Molecules. 2020; 26(1). PMC: 7792944. DOI: 10.3390/molecules26010013. View